Muna Therapeutics ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
Estimate generation in progress, please wait...
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  0.0% 4.1% 3.4% 3.7% 3.9%  
Credit score (0-100)  0 49 53 51 49  
Credit rating  N/A BBB BBB BBB BBB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  0.0 -8,796 -49,693 -98,234 -110,624  
EBITDA  0.0 -10,187 -58,449 -118,660 -135,959  
EBIT  0.0 -10,187 -61,469 -122,450 -142,518  
Pre-tax profit (PTP)  0.0 -10,231.2 -66,382.8 -133,182.3 -145,750.7  
Net earnings  0.0 -7,382.1 -61,518.3 -127,682.3 -140,320.0  
Pre-tax profit without non-rec. items  0.0 -10,231 -66,383 -133,182 -145,751  

 
See the entire income statement

Balance sheet (kDKK) 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  0.0 0.0 1,358 3,219 3,906  
Shareholders equity total  0.0 16,658 162,313 202,045 126,960  
Interest-bearing liabilities  0.0 5,000 7,533 16,601 12,036  
Balance sheet total (assets)  0.0 24,321 184,064 247,518 168,210  

Net Debt  0.0 -8,125 -101,000 -151,669 -91,006  
 
See the entire balance sheet

Volume 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  0.0 -8,796 -49,693 -98,234 -110,624  
Gross profit growth  0.0% 0.0% -465.0% -97.7% -12.6%  
Employees  0 3 7 16 18  
Employee growth %  0.0% 0.0% 133.3% 128.6% 12.5%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0 24,321 184,064 247,518 168,210  
Balance sheet change%  0.0% 0.0% 656.8% 34.5% -32.0%  
Added value  0.0 -10,186.8 -58,449.0 -119,429.9 -135,958.5  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 8,000 3,404 2,422 -11,229  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  0.0 -1.0 -2.0 -3.0 -4.0  

Profitability 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  0.0% 115.8% 123.7% 124.7% 128.8%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  0.0% -41.8% -63.3% -61.4% -69.8%  
ROI %  0.0% -47.0% -68.9% -68.3% -81.2%  
ROE %  0.0% -44.3% -68.7% -70.1% -85.3%  

Solidity 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  0.0% 68.5% 88.2% 81.6% 75.5%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  0.0% 79.8% 172.8% 127.8% 66.9%  
Gearing %  0.0% 30.0% 4.6% 8.2% 9.5%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 2.4% 6.1% 4.9% 3.9%  

Liquidity 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  0.0 2.1 5.3 4.0 2.7  
Current Ratio  0.0 2.1 5.3 4.0 2.7  
Cash and cash equivalent  0.0 13,125.3 108,532.4 168,269.8 103,042.9  

Capital use efficiency 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  0.0 8,700.6 94,151.0 137,704.3 71,662.4  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 -3,396 -8,350 -7,464 -7,553  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 -3,396 -8,350 -7,416 -7,553  
EBIT / employee  0 -3,396 -8,781 -7,653 -7,918  
Net earnings / employee  0 -2,461 -8,788 -7,980 -7,796